Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 18/20 | 0.77 |
| ▸ | GABRP | O00591 | 1/20 | 0.77 |
| ▸ | GABRD | O14764 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.77 |
| ▸ | PGR | P06401 | 1/20 | 0.77 |
| ▸ | KLK3 | P07288 | 1/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.77 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.77 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.77 |
| ▸ | CNR1 | P21554 | 1/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.77 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.77 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.77 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.77 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.77 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.77 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.77 |
| ▸ | GABRE | P78334 | 1/20 | 0.77 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30184917 | 1.00 | AR (0.77) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL1716398 | 0.89 | AR (0.74) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL20003393 | 0.89 | AR (0.64) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL13153201 | 0.88 | AR (0.69) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL30184903 | 0.87 | AR (0.69) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL1715104 | 0.87 | AR (0.69) | ARGABRPGABRDNR1I2NR3C1 | |
| Enzalutamide SCHEMBL29352764 | 0.87 | AR (1.00) | ARGABRPGABRDNR1I2NR3C1 | |
| Enzalutamide SCHEMBL189749 | 0.87 | AR (1.00) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL1716086 | 0.87 | AR (0.84) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL7035063 | 0.87 | AR (0.87) | ARGABRPGABRDNR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| CN-116003328-A | Diaryl hydantoin compounds | 加利福尼亚大学董事会 | 2023-04-25 | — | — | CN | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| CN-110003114-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2023-01-17 | — | — | CN | disclosed |
| EP-3970721-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210069154-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| WO-2020142228-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-07-09 | — | — | WO | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1893196-A4 | DIARYLHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007127010-A9 | DIARYLTHIOHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1893196-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007127010-A2 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006124118-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | AR, NR5A1, SHBG | AR 1/4885GABRP 1935/4885GABRD 2045/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | AR 1/4885GABRP 480/4885GABRD 448/4885 |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
| US-20210069154-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885GABRP 3568/4885GABRD 3622/4885 |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.